TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04064437

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical tests
Description: The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical tests
Description: The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical tests
Description: The investigators perform blood and urine tests in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical tests
Description: The investigators perform blood and urine tests in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: DXA scan
Description: The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: DXA scan
Description: The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: AGE Reader
Description: The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: AGE Reader
Description: The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
Study: NCT03151785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face BLS training
Description: Pupils will receive CPR training by standardised face-to-face BLS training only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifesaver training
Description: Pupils will receive CPR training by Lifesaver programme only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifesaver and Face-to-Face BLS training
Description: Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
Study: NCT04152252

Intervention type: OTHER
Intervention: Real time feedback
Description: Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.

Intervention type: OTHER
Intervention: Real time feedback
Description: Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.

Intervention type: BEHAVIORAL
Intervention: Post-event debriefing
Description: Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
Study: NCT04366778

Intervention type: DIAGNOSTIC_TEST
Intervention: TEM-tPA
Description: 325 patients with Covid-19 hospitalized in Lyon University Hospitals will have TEM-tPA measurements in parallel to D-dimers every 3 days during the hospitalization period. TEM-tPA of patients with and without thrombosis will be compared and their fibrinolysis (PAI-1, TAFI, tPA, thrombin) will be further explored.

Intervention type: DIAGNOSTIC_TEST
Intervention: TEM-tPA
Description: 325 patients with Covid-19 hospitalized in Lyon University Hospitals will have TEM-tPA measurements in parallel to D-dimers every 3 days during the hospitalization period. TEM-tPA of patients with and without thrombosis will be compared and their fibrinolysis (PAI-1, TAFI, tPA, thrombin) will be further explored.
Study: NCT05243498

Intervention type: OTHER
Intervention: Assessment of the optimised Allogenomic Mismatch Score (AMS)
Description: Optimised Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient, encountering only peptides that can be presented by the donors' MHC (using another layer of algorithm, NetMHCpan).

Intervention type: OTHER
Intervention: Assessment of the optimised Allogenomic Mismatch Score (AMS)
Description: Optimised Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient, encountering only peptides that can be presented by the donors' MHC (using another layer of algorithm, NetMHCpan).

Intervention type: OTHER
Intervention: Assessment of the optimised Allogenomic Mismatch Score (AMS)
Description: Optimised Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient, encountering only peptides that can be presented by the donors' MHC (using another layer of algorithm, NetMHCpan).

Intervention type: OTHER
Intervention: Assessment of the optimised Allogenomic Mismatch Score (AMS)
Description: Optimised Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient, encountering only peptides that can be presented by the donors' MHC (using another layer of algorithm, NetMHCpan).
Study: NCT00935129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OmniPod system
Description: Patients will be treated with the OmniPod system for 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient's conventional pump
Description: patients will be treated with their conventional pump for 12 weeks
Study: NCT00653419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buspirone HCl
Description: Tablets, 30 mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspar
Description: Tablets, 30 mg, single-dose
Study: NCT00967915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frentomy
Description: Frenotomy will be performed. This procedure involves crushing frenulum tissue with straight hemostat for hemostasis and anesthesia while tongue is elevated with elevator. Frenulum then cut to desired length with iris scissors. Patient then returned to parents and immediately breastfeeds without parent observing infant's mouth.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Infant taken into room away from parents and no frenotomy performed. Infant's mouth is examined but no interventions made.
Study: NCT01651650

Intervention type: DEVICE
Group type: OTHER
Intervention: Inhalation through Chiesi NEXThaler DPI
Description: Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
Study: NCT03992599

Intervention type: PROCEDURE
Intervention: Laparoscopic modified complete mesocolic excision
Description: First, complete kocherization may be required to clear possible tumor spread if the tumor is infiltrating or adhering to the duodenum or perinephric fat tissue. Second, if the tumor is locally advanced, the entire prerenal soft tissue behind Gerota's fascia may need to be cleared, especially for tumors growing toward the posterior. The third difference of mCME with the conventional CME involves the tailored resection of the mesocolon and ileal mesentery according to tumor location. After identifying the root of the middle colic artery, the site of the vascular ligation depends on the location of the tumor. When the tumor is located in the cecum and ascending colon, only the right branch of the middle colic artery is ligated. If the tumor was present in these latter sites, the root of the middle colic artery is ligated.
Study: NCT01064180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol Tablets 25 mg
Study: NCT03944707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 100 mg
Description: LOU064 100 mg once daily orally administered as two 50 mg capsules
Study: NCT04388982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage MSCs-Exos administrated for nasal drip
Description: Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
Study: NCT02282501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enteral feeding by nasogastric tube.
Description: method of administration enteral feeding by nasogastric tube.
Study: NCT03944707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily administered orally as capsules
Study: NCT01545752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teaching by non-interactive CD
Description: teaching book with non-interactive CD
Study: NCT01064180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol Tablets 25 mg
Study: NCT01278511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canadian C-Spine rule
Description: Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
Study: NCT03481725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)
Description: ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
Study: NCT01545752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive CD
Description: Teaching book with interactive CD
Study: NCT00725725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
Study: NCT01087125

Intervention type: DRUG
Intervention: No Interventions
Description: No Interventions
Study: NCT04230551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTSMA
Description: Alcohol Septal Ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTSMA
Description: Alcohol Septal Ablation
Study: NCT00686608

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose
Description: 0.3mg/kg of glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fructose
Description: fructose IV bolus

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: IV saline
Study: NCT00020787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT Immunogen
Description: Dose: 500 micrograms in 0.2mL Route: Deep intramuscular Schedule: Days 8, 36, and 64; an additional dose at week 2, cycle 7 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: dose: 100 mg/m2 Route: i.v. infusion in 500 mL in 0.9% NaCl administered up to 3 hours Schedule: day 1, and then every 4 weeks.
Study: NCT00725725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
Study: NCT03481725

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)
Description: SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
Study: NCT04026022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal System
Description: Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plaster in the ER or PACU
Study: NCT00725725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 25935
Description: 4 mg Org 25935 is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 25935
Description: 12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
Study: NCT00020787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
Study: NCT00968604

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BikDD Nanoparticle
Description: Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
Study: NCT00345397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic colostomy (PEC) tube
Description: PEC placement for antegrade enemas uses commercially available PEG tubes
Study: NCT03920917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon Pulmonary Vein isolation
Description: 1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation
Description: 1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~3. Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~4. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~5. Evaluated the procedure and radiofrequency ablation time.~6. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Study: NCT00841581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
Study: NCT00952653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained Release
Description: 50 mg DVS SR tablet days 1-6, period 2 only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
Study: NCT01211626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANA773
Description: ANA773 Tosylate Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANA773
Description: ANA773 Tosylate Capsule
Study: NCT00725725

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
Study: NCT03060148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic neurostimulation system
Description: Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
Study: NCT00844727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rofecoxib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills
Study: NCT03354962

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Ipilimumab
Description: Nivolumab + Ipilimumab alone (standard dosage regimen)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined treatment schema
Description: SBRT (recommended optimal dose) with Nivolumab + Ipilimumab (standard dosage regimen)
Study: NCT04388527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Convalescent Plasma
Description: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.
Study: NCT02528318

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lucinactant for inhalation
Description: Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lucinactant for inhalation
Description: Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lucinactant for inhalation
Description: Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lucinactant for inhalation
Description: Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP alone
Description: nCPAP therapy
Study: NCT03966469

Intervention type: OTHER
Intervention: Preoperative support person present
Description: Participants who bring a support person to their preoperative appointment.

Intervention type: OTHER
Intervention: Patient Present Only
Description: Patient presents to their preoperative appointment without a support person.
Study: NCT02846467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informed consent trough a portable video media
Description: Information provided to patients using the mobile application (iURO app)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written informed consent
Description: Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
Study: NCT03428048

Intervention type: PROCEDURE
Intervention: Hybrid procedure
Description: Ablation of the posterior aspect of the heart, an area thought to be the origin of chaotic arrhythmias in persistent Afib patients.

Intervention type: PROCEDURE
Intervention: Endocardial ablations
Description: ablations occurring inside the heart isolating the pulmonary veins - blocking energy from creating irregular or chaotic heart beats with use of a catheter

Intervention type: PROCEDURE
Intervention: left atrial appendage occlusion
Description: A procedure to isolate the left atrial appendage of the heart. this anatomic body is the origin of clot formation which can lead to stroke. the clot formation as a result of Afib
Study: NCT04048174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical probiotic treatment with Lactococcus lactis W136
Description: Nasal and sinus irrigation with reconstituted live probiotic bacteria

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Topical probiotic treatment with Lactococcus lactis W136
Description: Nasal and sinus irrigation with reconstituted live probiotic bacteria

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline irrigation
Description: Nasal and sinus irrigation with saline solution

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline irrigation
Description: Nasal and sinus irrigation with saline solution
Study: NCT04307030

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Auscultation and Echocardiography
Description: Heart auscultation will be done by cardiovascular pediatrician and echocardiography by echocardiologist
Study: NCT02400073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoSet for Her
Description: 3 months nightly usage of the AutoSet for Her device
Study: NCT00383019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalatan
Description: latanoprost 0.005%, one rop once daily in evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalacom
Description: latanoprost 0.005% adn timolol 0.5%, one drop, once daily
Study: NCT05036239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric biceps curls
Description: 10 x 5 repetitions of eccentric biceps curls, interspaced by 30 seconds of rest.
Study: NCT01426321

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imaging guided LV lead positioning
Description: LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate optimal cardiac vein segment is then chosen using the CT images.
Study: NCT00051636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Oral risedronate 30 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Risedronate
Description: Oral placebo of risedronate capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Zoledronic Acid
Description: 5 mL of sterile water one dose intravenous infusion.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Calcium and vitamin D supplements were supplied.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Calcium and vitamin D supplements were supplied.
Study: NCT01453374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIVITROL 380mg
Description: 380 mg IM injection given once monthly
Study: NCT03523013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP treatment with different pressure for OSA patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP treatment with different pressure for OSA patients